Evidence map›Paper›PMID 36928885›Full record

ArticlePloS one2023

Development of an ectopic huLiver model for Plasmodium liver stage infection.

Gabriela Samayoa-Reyes, Siobhan M Flaherty, Kristina S Wickham, Sara Viera-Morilla, Pamela M Strauch, Alison Roth, Laura Padrón, Conner M Jackson, Patricia Meireles, David Calvo and 6 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Gabriela Samayoa-ReyesDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
Siobhan M FlahertyDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
Kristina S WickhamDepartment of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Sara Viera-MorillaDiseases of the Developing World, Infectious Diseases-Centre for Excellence in Drug Discovery (ID CEDD), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Pamela M StrauchDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
Alison RothDepartment of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Laura PadrónDiseases of the Developing World, Infectious Diseases-Centre for Excellence in Drug Discovery (ID CEDD), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Conner M JacksonDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.ORCID 0000-0002-3519-5667
Patricia MeirelesDiseases of the Developing World, Infectious Diseases-Centre for Excellence in Drug Discovery (ID CEDD), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
David CalvoDiseases of the Developing World, Infectious Diseases-Centre for Excellence in Drug Discovery (ID CEDD), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Wanlapa RoobsoongFaculty of Tropical Medicine, Mahidol Vivax Research Unit, Mahidol University, Bangkok, Thailand.
Niwat KangwanrangsanFaculty of Science, Pathobiology Department, Mahidol University, Bangkok, Thailand.
Jetsumon SattabongkotFaculty of Tropical Medicine, Mahidol Vivax Research Unit, Mahidol University, Bangkok, Thailand.
Gregory ReichardDepartment of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Maria José Lafuente-MonasterioDiseases of the Developing World, Infectious Diseases-Centre for Excellence in Drug Discovery (ID CEDD), GlaxoSmithKline, Tres Cantos, Madrid, Spain.
Rosemary RochfordDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.ORCID 0000-0002-0001-5152
GlaxoSmithKline (Spain) · ESUniversity of Colorado Denver · USMahidol University · THWalter Reed Army Institute of Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early Plasmodium falciparum and P. vivax infection requires parasite replication within host hepatocytes, referred to as liver stage (LS). However, limited understanding of infection dynamics in human LS exists due to species-specificity challenges. Reported here is a reproducible, easy-to-manipulate, and moderate-cost in vivo model to study human Plasmodium LS in mice; the ectopic huLiver model. Ectopic huLiver tumors were generated through subcutaneous injection of the HC-04 cell line and shown to be infectible by both freshly dissected sporozoites and through the bite of infected mosquitoes. Evidence for complete LS development was supported by the transition to blood-stage infection in mice engrafted with human erythrocytes. Additionally, this model was successfully evaluated for its utility in testing antimalarial therapeutics, as supported by primaquine acting as a causal prophylactic against P. falciparum. Presented here is a new platform for the study of human Plasmodium infection with the potential to aid in drug discovery.

Indexed as

Communicable DiseasesLiver DiseasesMalariaMalaria, FalciparumMalaria, VivaxPlasmodiumAnimalsHepatocytesHumansLiverMicePlasmodium falciparumSporozoites

Identifiers

PMID36928885
PMCPMC10019673
OpenAlexW4327550238

What OpenQuestion holds

Textfull text, public
LicenceCC0
measurements read60
identifiers read5
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.